2016 Fiscal Year Final Research Report
Target therapy for high grade glioma by using specific antibody against glioma stem cell
| Project/Area Number |
26462187
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 脳腫瘍 / 神経膠腫 / 膠芽腫 / ACTC1 / IL13R alpha 2 / 予後 / 浸潤 / 細胞骨格 |
|---|
| Outline of Final Research Achievements |
Target molecules for therapy of gliomas were identified in our study. Actin, alpha cardiac muscle 1 (ACTC1) which was a part of cytoskeletons became a marker of poor prognosis of gliomas. In glioblastoma which median survival was only one year, the difference of overall survival was over two years by presence or absence of ACTC1.ACTC1 was also related to the tumor invasion in high grade gliomas. These results were presented on Journal of Neurosurgery 2017 which was one on top journals in the field of neurosurgery. In addition, interleukin 13 receptor alpha 2 was also related to the poor prognosis in high grade gliomas. This identification will be on Journal of Neurosurgical Sciences in 2017.
|
| Free Research Field |
脳腫瘍
|
